Literature DB >> 36125595

A Method Using Longitudinal Laboratory Data to Predict Future Intestinal Complication in Patients with Crohn's Disease.

James Irwin1,2,3, Anton Lord4, Emma Ferguson5, Lisa A Simms4, Katherine Hanigan4, Carlos A Montoya6,7, Graham Radford-Smith4,5,8.   

Abstract

BACKGROUND: Stenosis, fistulization, and perforation of the bowel are severe outcomes which can occur in patients with Crohn's disease. Accurate prediction of these events may enable clinicians to alter treatment strategies and avoid these outcomes. AIMS: To study the correlation between longitudinal laboratory testing and subsequent intestinal complications in patients with Crohn's disease.
METHODS: An observational cohort of patients with Crohn's disease at a single center were analyzed between 01/01/1994 and 06/30/2016. A complication was defined as the development of an intestinal fistula, stenosis, or perforation. Exploratory analysis using Cox regression was performed to select the best statistical method to represent longitudinal laboratory data. Cox regression was used to identify laboratory variables independently associated with the development of a subsequent complication. A clinical scoring tool was designed.
RESULTS: In 246 patients observed over a median of 5.72 years, 134 complications occurred. Minimum or maximum value in a preceding window period of one year was most strongly associated with subsequent complication. A Longitudinal Laboratory score of ≥ 2 (maximum albumin level < 39 g/L = 1, maximum mean cell volume < 88 fL = 1, minimum platelet count > 355 × 109/L = 1, minimum C reactive protein > 5 mg/L = 1) was 62% sensitive and 91% specific in identifying patients who develop a subsequent complication.
CONCLUSION: A consistent reduction in serum albumin and mean cell volume, and a consistent increase in platelet count and C reactive protein were associated with a subsequent complication in patients with Crohn's disease. Longitudinal laboratory tests may be used as described in this paper to provide a rational for earlier escalation of therapy.
© 2022. The Author(s).

Entities:  

Keywords:  Biomarkers; Crohn’s disease; Fistula; Inflammatory bowel diseases; Perforation; Stenosis

Year:  2022        PMID: 36125595     DOI: 10.1007/s10620-022-07639-w

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  28 in total

1.  A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.

Authors:  B G Feagan; R N Fedorak; E J Irvine; G Wild; L Sutherland; A H Steinhart; G R Greenberg; J Koval; C J Wong; M Hopkins; S B Hanauer; J W McDonald
Journal:  N Engl J Med       Date:  2000-06-01       Impact factor: 91.245

2.  Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn's disease.

Authors:  James F Markowitz
Journal:  Rev Gastroenterol Disord       Date:  2003

3.  Is it possible to change phenotype progression in Crohn's disease in the era of immunomodulators? Predictive factors of phenotype progression.

Authors:  Fernando Magro; Eduardo Rodrigues-Pinto; Rosa Coelho; Patrícia Andrade; João Santos-Antunes; Susana Lopes; Claudia Camila-Dias; Guilherme Macedo
Journal:  Am J Gastroenterol       Date:  2014-05-06       Impact factor: 10.864

Review 4.  Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease.

Authors:  W Sandborn; L Sutherland; D Pearson; G May; R Modigliani; C Prantera
Journal:  Cochrane Database Syst Rev       Date:  2000

5.  Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates.

Authors:  A V Ramadas; S Gunesh; G A O Thomas; G T Williams; A B Hawthorne
Journal:  Gut       Date:  2010-07-21       Impact factor: 23.059

6.  Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery.

Authors:  J Cosnes; I Nion-Larmurier; L Beaugerie; P Afchain; E Tiret; J-P Gendre
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

7.  Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort.

Authors:  Kelvin T Thia; William J Sandborn; William S Harmsen; Alan R Zinsmeister; Edward V Loftus
Journal:  Gastroenterology       Date:  2010-07-14       Impact factor: 22.682

8.  Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype.

Authors:  Kelly M Tarrant; Murray L Barclay; Christopher M A Frampton; Richard B Gearry
Journal:  Am J Gastroenterol       Date:  2008-12       Impact factor: 10.864

9.  Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.

Authors:  B G Feagan; J Rochon; R N Fedorak; E J Irvine; G Wild; L Sutherland; A H Steinhart; G R Greenberg; R Gillies; M Hopkins
Journal:  N Engl J Med       Date:  1995-02-02       Impact factor: 91.245

10.  Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center.

Authors:  Mark Lazarev; Thomas Ullman; Wolfgang H Schraut; Kevin E Kip; Melissa Saul; Miguel Regueiro
Journal:  Inflamm Bowel Dis       Date:  2010-05       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.